Fragasso Group Inc. Abb Vie Inc. Transaction History

Fragasso Group Inc.

$1.29 Billion
Q3 2025

A detailed history of Fragasso Group Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Fragasso Group Inc. holds 21,158 shares of ABBV stock, worth $4.95 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares

21,158

Previous 21,424 1.24%

Holding current value

$4.95 Million

Previous $3.98 Million 23.19%

% of portfolio

0.38%

Previous 0.33%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 06, 2025	SELL	$184.85 - $231.54 $49,170 - $61,589	-266 Reduced 1.24%	21,158 $4.9 Million
Q2 2025 Jul 09, 2025	BUY	$170.16 - $206.27 $49,516 - $60,024	291 Added 1.38%	21,424 $3.98 Million
Q1 2025 Apr 09, 2025	BUY	$169.2 - $216.66 $1.41 Million - $1.81 Million	8,361 Added 65.46%	21,133 $4.43 Million
Q4 2024 Jan 13, 2025	BUY	$164.99 - $203.87 $29,698 - $36,696	180 Added 1.43%	12,772 $2.27 Million
Q3 2024 Oct 07, 2024	BUY	$163.84 - $199.33 $67,010 - $81,525	409 Added 3.36%	12,592 $2.49 Million
Q2 2024 Jul 08, 2024	BUY	$154.79 - $180.76 $35,446 - $41,394	229 Added 1.92%	12,183 $2.09 Million
Q1 2024 Apr 10, 2024	SELL	$159.82 - $182.1 $4,315 - $4,916	-27 Reduced 0.23%	11,954 $2.18 Million
Q4 2023 Jan 08, 2024	SELL	$137.6 - $154.97 $22,428 - $25,260	-163 Reduced 1.34%	11,981 $1.86 Million
Q3 2023 Dec 06, 2023	BUY	$133.59 - $154.65 $23,912 - $27,682	179 Added 1.5%	12,144 $1.81 Million
Q2 2023 Jul 10, 2023	BUY	$132.51 - $164.9 $35,910 - $44,687	271 Added 2.32%	11,965 $1.61 Million
Q1 2023 Apr 13, 2023	BUY	$144.61 - $166.54 $4,627 - $5,329	32 Added 0.27%	11,694 $1.86 Million
Q4 2022 Jan 24, 2023	SELL	$138.31 - $165.87 $1.61 Million - $1.93 Million	-11,662 Closed	0 $0
Q4 2022 Jan 24, 2023	BUY	$138.31 - $165.87 $4,149 - $4,976	30 Added 0.26%	11,662 $0
Q3 2022 Oct 13, 2022	BUY	$134.21 - $153.93 $7,515 - $8,620	56 Added 0.48%	11,632 $1.56 Million
Q2 2022 Aug 30, 2022	SELL	$137.62 - $174.96 $6,743 - $8,573	-49 Reduced 0.42%	11,576 $1.77 Million
Q1 2022 Apr 06, 2022	BUY	$131.98 - $163.75 $20,324 - $25,217	154 Added 1.34%	11,625 $1.88 Million
Q4 2021 Jan 19, 2022	SELL	$107.43 - $135.93 $68,647 - $86,859	-639 Reduced 5.28%	11,471 $1.55 Million
Q3 2021 Oct 08, 2021	BUY	$106.4 - $120.78 $68,628 - $77,903	645 Added 5.63%	12,110 $1.31 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $2,419 - $2,695	23 Added 0.2%	11,465 $1.29 Million
Q1 2021 May 27, 2021	BUY	$102.3 - $112.62 $10,536 - $11,599	103 Added 0.91%	11,442 $1.24 Million
Q4 2020 Feb 04, 2021	BUY	$80.49 - $108.67 $4,990 - $6,737	62 Added 0.55%	11,339 $1.22 Million
Q3 2020 Nov 05, 2020	BUY	$85.91 - $100.83 $5,927 - $6,957	69 Added 0.62%	11,277 $988,000
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $348,214 - $465,962	4,746 Added 73.44%	11,208 $1.04 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $9,737 - $12,183	135 Added 2.13%	6,462 $572,000
Q3 2019 Nov 13, 2019	BUY	$62.98 - $75.72 $3,904 - $4,694	62 Added 0.99%	6,327 $479,000
Q2 2019 Aug 13, 2019	BUY	$65.7 - $83.98 $4,599 - $5,878	70 Added 1.13%	6,265 $456,000
Q1 2019 May 08, 2019	BUY	$77.14 - $90.79 $5,399 - $6,355	70 Added 1.14%	6,195 $499,000
Q4 2018 Feb 12, 2019	SELL	$77.85 - $96.01 $544 - $672	-7 Reduced 0.11%	6,125 $565,000
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $42,232 - $46,949	475 Added 8.4%	6,132 $549,000
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $6,808 - $9,117	-74 Reduced 1.29%	5,657 $535,000
Q4 2017 Feb 09, 2018	BUY	$89.56 - $98.21 $10,120 - $11,097	113 Added 2.01%	5,731 $554,000
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $392,417 - $501,237	5,618	5,618 $499,000

Others Institutions Holding ABBV

# of Institutions

4,481

Shares Held

1.28B

Call Options Held

17.1M

Put Options Held

15.4M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $414B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fragasso Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fragasso Group Inc. with notifications on news.

Account

Fragasso Group Inc. Abb Vie Inc. Transaction History